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OBJECTIVES We sought to evaluate C-reactive protein (CRP) and troponin T (TnT) as predictors of risk
of the individual end points of mortality and myocardial infarction (MI) in a large cohort of
patients with acute coronary syndrome (ACS).
BACKGROUND Both CRP and TnT predict risk of future coronary events in patients with ACS. However,
the relationships between the levels of the markers and the individual end points are still
unclear.
METHODS Baseline levels of CRP and TnT were determined in 7,108 patients with ACS not undergoing
early revascularization in the Global Use of Strategies To Open occluded arteries trial IV
(GUSTO-IV) trial and related to outcome at 30 days.
RESULTS Quartiles of TnT related to 30-day mortality, which was 1.1%, 3.7%, 3.7%, and 7.4% (p 
0.001) and to the rate of MI: 2.5%, 6.7%, 7.2%, and 5.6% (p 0.001). Quartiles of CRP also
related to 30-day mortality, which was 2.0%, 3.3%, 3.9%, and 6.3% (p  0.001), whereas
there was no relationship to the 30-day rate of MI: 5.6%, 4.7%, 5.2%, and 5.9% (p  0.48).
On multivariable analysis, both TnT and CRP were independent predictors of mortality, but
only TnT was a predictor of MI. The combination of CRP and TnT provides an even better
risk stratification of mortality, with 0.3% and 9.1% death rates, respectively, when both
markers are in the bottom versus top quartiles.
CONCLUSIONS In ACS, baseline levels of TnT and CRP are independently related to 30-day mortality. Any
detectable elevation of TnT, but not of CRP, is also associated with an increased risk of
subsequent MI. Regarding mortality, the combination of both markers provides a better risk
stratification than either one alone. (J Am Coll Cardiol 2003;41:916–24) © 2003 by the
American College of Cardiology Foundation
Inflammation has an essential role in the pathogenesis of
atherosclerosis (1) and is also a consequence of myocardial
damage. Elevated markers of inflammatory activity are
associated with an increased risk of future cardiovascular
events in healthy individuals (2,3) and in patients with
stable (4) and unstable coronary artery disease (CAD)
(5–8). In unstable CAD, C-reactive protein (CRP) eleva-
tion on hospital admission has been shown to be an
independent predictor of mortality (5–8). However, the
association between the CRP level and the early risk of
myocardial infarction (MI) in unstable CAD has not been
established, because most studies have presented small
patient numbers and combined end points (4,7,9,10). Nu-
merous previous studies have shown that troponin elevation
is associated with an impaired outcome in patients with
unstable CAD (11). Also, few studies have had a sample
size and event rate allowing the separate evaluation of
subsequent death and MI in relation to troponin levels. The
present pre-defined analyses from the Global Use of Strat-
egies To Open occluded arteries trial IV (GUSTO-IV) (12)
is the largest study on the associations between baseline
levels of troponin T (TnT) and high-sensitivity CRP and
the separate events of death and MI in patients with
unstable CAD.
METHODS
Patient selection and randomized treatment. The
GUSTO-IV trial included 7,800 patients with unstable
CAD from 458 centers in 24 countries during 1999 and
2000. The detailed design and main results of the trial have
been published (12). Eligible patients were21 years of age
with one or more episodes of angina lasting 5 min within
24 h of admission and either a positive cardiac TnT or TnI
test (above the upper limit of normal for the local assay) or
0.5 mm of transient or persistent ST-segment depression.
The study was conducted in a double-blind fashion with
From the Department of Medical Sciences, *Cardiology and Clinical Chemistry,
Uppsala, Sweden; †Department of Medicine, Alberta, Canada; ‡Centocor, Malvern,
Pennsylvania; §Duke CRI, Durham, North Carolina; ¶Thoraxcenter, Erasmus
Medical Center, Rotterdam, The Netherlands; and #Cleveland Clinic Foundation,
Cleveland, Ohio.
Manuscript received August 12, 2002; revised manuscript received October 9,
2002, accepted November 11, 2002.
Journal of the American College of Cardiology Vol. 41, No. 6, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Science Inc. doi:10.1016/S0735-1097(02)02969-8
patients randomly assigned to three treatment groups:
abciximab infusion for 24 h or 48 h or corresponding
placebo infusion. All patients received aspirin, 150 to 325
mg/day orally for long-term treatment, as well as either
unfractionated heparin infusion for 48 h (n  6,826) or
subcutaneous dalteparin every 12 h for five to seven days (n
 974). Coronary angiography was not to be performed
during or within 12 h after completion of study agent
infusion.
Laboratory analyses. Venous blood samples were collected
in evacuated tubes through a direct venous puncture at
baseline and 8, 16, 24, 36, and 48 h after randomization.
After centrifugation, serum was frozen at20°C in aliquots
and sent for central laboratory analyses of creatine kinase,
MB isoenzyme (CK-MB) levels. One aliquot of the serum
samples at baseline was stored at70°C and sent in batches
of 500 to the Department of Clinical Chemistry, Uppsala,
Sweden, for analyses of TnT and CRP. One batch was
unfortunately lost during transportation. The levels of TnT
were determined by a third-generation assay on an Elecsys
(Roche Diagnostics, Basel, Switzerland), with the detection
limit at 0.01 g/l and a total coefficient of variance (CV) of
8% at 0.05 g/l and 4.1% to 6.0% between 0.1 and 11 g/l.
The CRP concentrations were measured with a chemilumi-
nescent enzyme-labeled immunometric assay (Immulite
CRP, Diagnostic Products Corp., Los Angeles, California).
The detection limit was 0.1 mg/l, with a total CV of 5.6%
at 2 mg/l and 5% at 10 mg/l.
Definition of end points. A 12-lead electrocardiogram
was obtained at randomization, 48 h, or seven days and at
30 days. Myocardial infarction was defined as either a new,
significant Q-wave (0.04 s or at least a quarter of the R
wave amplitude in two or more contiguous leads) or
CK-MB at least three times the upper limit of normal. For
patients with CK-MB elevation at study entry, a new
episode of chest pain in combination with a new CK-MB
elevation was required for MI diagnosis during the initial
seven days, as presented in detail in the GUSTO-IV–ACS
report (12). After coronary artery bypass graft surgery, a
new, significant Q-wave was the only criterion. A clinical
end-point committee blinded to treatment assignment ad-
judicated all suspected cases of MI.
Statistical methods. The present evaluation of CRP and
TnT on outcome was performed using pre-defined analyses.
The material was divided into strata based on quartiles of
the respective CRP and TnT levels. For continuous vari-
ables, means were expressed with one standard deviation,
and for variables not normally distributed, medians were
shown with 25th to 75th percentiles. The outcomes of death
and/or MI at 48 h, seven days, and 30 days were compared
between the different strata of patients. Differences were
evaluated with the chi-square test (linear by linear associa-
tion). Odds ratios (OR), with 95% confidence intervals
(CI), were presented. A p value 0.05 was considered
statistically significant. The independence of relationships
between the patient strata of the two markers and the
outcomes of death/MI, death, and MI at 30 days was
assessed in three different models of multiple logistic regres-
sion analysis. A number of known risk factors were entered
into the models: age, male gender, body weight, smoking,
previous angina, stroke, heart failure, diabetes mellitus,
hypertension, hypercholesterolemia, previous revasculariza-
tion, previous MI, current treatment with beta-blockers and
angiotensin-converting enzyme inhibitors, aspirin treatment
before inclusion, ST-segment depression 0.5 mm, and
randomized treatment (abciximab for 24 or 48 h or place-
bo). Model 1 also included quartiles of TnT and CRP.
Model 2 included the bottom versus the three upper
quartiles of either marker in addition to the quartiles of the
other variable. Finally, model 3 included the top versus the
three lower quartiles in addition to the quartiles of the other
variable. Additional logistic regression analyses were per-
formed to test for the interaction between TnT and CRP
quartiles.
RESULTS
The mean age of the study population was 65.2  11.3
years, and 36.7% were females (Tables 1 and 2). ST-
segment depression 0.5 mm was observed in 80.1%, and
troponin T was 0.1 g/l in 47.3% of the patients, as
inclusion was based on either ST-segment depression or a
positive troponin test. The median time from the onset of
the qualifying episode of ischemic chest pain to randomiza-
tion was 9.5 h (range 5.0 to 16.6). During infusion of the
study agent (48 h), only 1.8% of the patients (n  131)
underwent revascularization, as intended by the protocol.
However, at 30-day follow-up, 29.3% of the patients (n 
2,088) had undergone such a procedure.
Troponin T, CRP, and their relationships to baseline
characteristics. Troponin T analyses for 7,115 patients
(91.2%) and CRP analyses for 7,108 patients (91.1%) were
available. The TnT levels ranged from 0 to 17.3 g/l, and
the quartile limits were 0.01, 0.12, and 0.47 g/l. The range
of CRP levels was 0 to 489 mg/l, with quartile limits of
1.84, 3.96, and 9.62 mg/l. The Spearman correlation
coefficient for the concordance of the two markers was 0.24.
The baseline characteristics for the strata of patients based
Abbreviations and Acronyms
ACS  acute coronary syndrome
CAD  coronary artery disease
CI  confidence interval
CK-MB  creatine kinase, MB isoenzyme
CRP  C-reactive protein
CV  coefficient of variance
GUSTO-IV  Global Use of Strategies To Open
occluded arteries trial IV
MI  myocardial infarction
OR  odds ratio
TnT  troponin T
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on quartiles of both markers are shown in Tables 1 and 2.
Both markers were positively correlated to age and current
smoking and negatively to hypercholesterolemia, a history
of angina pectoris, and hypertension. In addition, CRP had
a positive correlation to diabetes and heart failure.
Troponin T in relation to outcome. The rate of the
primary combined end point of death or MI (Fig. 1a) in the
GUSTO-IV–ACS study was increasing with higher TnT
quartiles at all time points of follow-up (p  0.001). Also,
mortality was markedly increasing with increased TnT
quartiles from 1.1% to 7.4% between the first and fourth
quartile at 30 days (Fig. 1b). There was a large increase from
the first to second quartile (1.1% vs. 3.7%) and from the
third to fourth quartile (3.7% vs. 7.4%). The rate of MI was
increasing from the first to second quartile (2.5% vs. 6.7% at
30 days). No further increase was observed between the
upper three quartiles (Fig. 1c). There was even a trend
toward a lower rate of MI in the fourth quartile as compared
with the third quartile (5.6% vs. 7.2%). On multiple logistic
regression analysis, increasing TnT quartile was indepen-
dently related to both death (OR 1.63, 95% CI 1.43 to 1.87)
and MI (OR 1.23, 95% CI 1.11 to 1.37) at 30 days (Table
Table 1. Baseline Characteristics for Patient Strata Based on Quartiles of Troponin T
Quartiles of Troponin T (g/l)
p Value
<0.01
(n  1,992)
0.01–0.12
(n  1,625)
0.12–0.47
(n  1,743)
>0.47
(n  1,776)
Age (yrs) 63.6  10.8 66.2  11.1 65.0  11.5 66.2  11.4  0.001
Weight (kg) 75.9  13.1 77.0  13.4 78.4  13.7 77.2  14.0  0.001
Male gender (%) 48.3 64.2 68.7 69.2  0.001
Current smoking (%) 16.6 20.4 25.8 27.7  0.001
History of stroke (%) 1.5 2.8 2.6 2.7 0.014
Heart failure (%) 7.7 8.5 6.0 7.6 0.38
Previous revascularization (%) 16.4 16.7 15.6 12.7  0.001
Hypercholesterolemia (%)* 35.0 33.5 29.5 26.4  0.001
Angina pectoris (%) 60.6 53.2 37.9 36.2  0.001
Hypertension (%) 57.4 55.3 48.0 46.6  0.001
Diabetes mellitus (%) 18.4 23.1 21.4 21.9 0.025
Previous MI (%)
10 days (%) 28.1 33.7 28.5 28.9 0.7
2 days (%) 0.1 0.1 0.8 1.1  0.001
ACE inhibitor (%) 36.4 34.3 27.3 27.9  0.001
Two or more anti-anginal
drugs (%)†
48.0 42.2 33.3 34.5  0.001
Median CRP (mg/l)‡ 3.0 (1.4–6.9) 3.3 (1.6–7.5) 4.2 (2.1–9.4) 6.7 (2.9–17.4)  0.001
*History of hypercholesterolemia requiring medical therapy. †Beta-blockers, long-acting nitrates, or calcium inhibitors (no
differences in aspirin treatment). ‡25th to 75th percentile. Data are presented as the mean value  SD or percentage of patients,
except for CRP.
ACE  angiotensin-converting enzyme; CRP  C-reactive protein; MI  myocardial infarction.
Table 2. Baseline Characteristics in Relation to Patient Strata Based on Quartiles of C-Reactive Protein
Quartiles of CRP (mg/l)
p Value
<1.84
(n  1,779)
1.84–3.96
(n  1,777)
3.96–9.62
(n  1,743)
>9.62
(n  1,754)
Age (yrs) 63.9  11.4 64.7  11.0 65.1  11.3 66.9  11.0  0.001
Weight (kg) 75.0  13.0 77.7  13.4 78.7  13.7 77.4  14.0  0.001
Male gender (%) 63.7 62.1 61.3 61.3 0.11
Current smoking (%) 19.5 20.8 25.7 23.8  0.001
History of stroke (%) 2.2 1.7 2.2 3.2 0.036
Heart failure (%) 5.3 6.1 7.2 11.2  0.001
Previous revascularization (%) 15.8 16.1 15.2 14.5 0.2
Hypercholesterolemia (%)* 34.9 30.1 31.0 28.4  0.001
Angina pectoris (%) 49.0 48.8 44.7 46.8 0.045
Hypertension (%) 48.2 52.7 51.6 55.2  0.001
Diabetes mellitus (%) 14.8 19.5 21.7 28.2  0.001
Previous MI (%)
10 days (%) 29.3 28.9 29.7 31.0 0.23
2 days (%) 0.2 0.6 0.5 0.7 0.051
ACE inhibitor (%) 30.1 32.2 29.6 34.5 0.03
Two or more anti-anginal drugs (%)† 40.0 39.1 38.6 41.3 0.53
Median troponin T (ug/l)‡ 0.04 (0.01–0.2) 0.08 (0.01–0.3) 0.1 (0.01–0.5) 0.3 (0.03–0.8)  0.001
*†‡Footnotes and abbreviations as in Table 1. Data are presented as the mean value  SD or percentage of patients, except for troponin T.
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Figure 1. Rate of (a) death/myocardial infarction (MI), (b) death, and (c) MI at 48 h, 7 days, and 30 days, respectively, in relation to quartiles of troponin
T. The number of patients with events is noted under the bars.
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3). Also, when entered into the regression model as a
continuous variable, TnT was a significant independent
predictor of mortality (OR 1.25, 95% CI 1.10 to 1.42). The
first and third quartile limits independently predicted mor-
tality, whereas only the first quartile limit independently
predicted MI. The relationship between TnT and CRP
levels and cardiac events was similar when performed only
for the 5,756 patients included with the ST-segment de-
pression criterion. In this group, the 30-day mortality rates
for increasing TnT quartiles were 1.1%, 3.8%, 4.9%, and
8.6% (p  0.001) and the corresponding MI rates were
2.6%, 7.0%, 8.0%, and 6.6% (p  0.001). There was no
difference in outcome at 30-day follow-up between the
randomized treatment groups at different quartiles of TnT.
C-reactive protein in relation to outcome. The rate of the
primary combined end point—death or MI—was signifi-
cantly increasing with higher CRP quartiles at 30 days:
7.1%, 7.3%, 8.1%, and 10.5% (p  0.001) (Fig. 2a). This
difference was entirely driven by the difference in mortality,
which was observed already at 48 h (Fig. 2b). At 30 days,
mortality increased from 2% in the first quartile to 6.3% in
the fourth quartile, with increases also from the first to
second and from the third to fourth quartiles. However, at
no time point was there any relationship between the rate of
MI and the quartiles of CRP (Fig. 2c). On multiple logistic
regression analysis (Table 3), increasing CRP quartiles
independently predicted 30-day mortality (OR 1.19, 95%
CI 1.05 to 1.35). C-reactive protein, entered into the
logistic regression analysis as a continuous variable, was also
an independent predictor of 30-day mortality (OR 1.005,
95% CI 1.00 to 1.009). However, there was no relationship
between increasing CRP quartiles and the rate of MI at 30
days (OR 0.94, 95% CI 0.85 to 1.04). Mortality at 30 days
was also independently predicted by the first quartile limit
(1.84 vs. 1.84). For the 5,756 patients included with
ST-segment depression, the outcome was similar at 30 days
for the strata of patients based on increasing CRP quartiles.
Thus, in this subpopulation, the 30-day mortality rates were
2.2%, 3.4%, 4.2%, and 6.8% (p  0.001), and the corre-
sponding MI rates were 5.8%, 5.0%, 5.6%, and 6.4% (p 
0.4). There was no difference in outcome at 30-day
follow-up between the randomized treatment groups at
different quartiles of CRP.
Combination of TnT and CRP. As both TnT and CRP
were independent predictors of 30-day mortality (Table 3),
its relationship to the combination of the markers was also
evaluated. The highest mortality at 30 days (9.1%) was
found in patients with both markers in the top quartiles
(Table 4), and the lowest mortality (0.3%) was found in
patients with both makers in the bottom quartiles. Patients
in the bottom quartile of TnT (0.01 g/l) had a very low
event rate, but, still, an increased level of CRP (1.84 vs.
1.84 mg/l) was associated with raised 30-day mortality
(1.5% vs. 0.3%; OR 5.1, 95% CI 1.2 to 21.7). Also in the
top quartile of TnT (0.47 g/l), an increased level of CRP
(1.84 vs. 1.84 mg/l) was related to increased mortality
(7.9% vs. 3.6%; OR 2.30, 95% CI 1.15 to 2.60). Similarly,
in the bottom (1.84 mg/l) as well as the top quartile
(9.62 mg/l) of CRP, a raised TnT level (0.01 vs. 0.01
g/l) was associated with raised mortality (3.0% vs. 0.3%;
OR 10.3, 95% CI 2.5 to 43.2 and 7.5% vs. 1.4%; OR 5.7,
95% CI 2.3 to 14.2, respectively). There was no significant
(p  0.4) interaction between the markers, as evaluated by
the interaction term “CRP–TnT” entered into the logistic
regression model, in addition to CRP and TnT.
DISCUSSION
In concordance with other studies, the current study shows
that both TnT and CRP are significant predictors of an
adverse outcome in the early phase after an episode of acute
coronary syndrome (ACS) (6,8,9). In contrast to previous
studies, both CRP and TnT levels were available from a
sufficiently large number of patients to allow prospective
evaluation of their relationships to mortality and risk of MI
Table 3. Multiple Logistic Regression Analyses on Troponin T and C-Reactive Protein as Predictors of Death, MI, and Death or
MI at 30 Days
Death MI Death or MI
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Model 1
TnT quartiles* 1.63 (1.43–1.87)  0.001 1.23 (1.11–1.37)  0.001 1.39 (1.27–1.52)  0.001
CRP quartiles† 1.19 (1.05–1.35) 0.006 0.94 (0.85–1.04) 0.26 1.00 (0.92–1.09) 0.91
Model 2
TnT (g/l) 0.01 vs. 0.01‡ 3.36 (2.10–5.34)  0.001 2.48 (1.79–3.42)  0.001 2.84 (2.14–3.76)  0.001
CRP (mg/l) 1.84 vs. 1.84‡ 1.72 (1.17–2.55) 0.009 0.76 (0.59–0.98) 0.033 0.93 (0.75–1.16) 0.53
Model 3
TnT (g/l) 0.47 vs. 0.47‡ 2.47 (1.86–3.28)  0.001 1.22 (0.79–1.32) 0.89 1.51 (1.23–1.86)  0.001
CRP (mg/l) 9.62 vs. 9.62‡ 1.31 (0.98–1.74) 0.07 0.98 (0.76–1.25) 0.85 1.07 (0.87–1.31) 0.55
All three models included age, male gender, body weight, smoking, previous angina, stroke, heart failure, diabetes mellitus, hypertension, hypercholesterolemia, previous
revascularization, previous myocardial infarction, current treatment with beta-blockers and angiotensin-converting enzyme inhibitors, aspirin treatment before inclusion,
ST-segment depression 0.5 mm, and randomized treatment (abciximab for 24 or 48 h or placebo). *Patient strata based on quartiles of troponin T: 0.01, 0.01–0.12,
0.12–0.47, and 0.47 g/l. †Patient strata based on quartiles of CRP: 1.84, 1.84–3.96, 3.96–9.62, and 9.62 mg/l. ‡Quartiles of the other marker were included in the
analysis.
CI  confidence interval; CRP  C-reactive protein; MI  myocardial infarction; OR  odds ratio; TnT  troponin T.
920 James et al. JACC Vol. 41, No. 6, 2003
Troponin and CRP in Acute Coronary Syndrome March 19, 2003:916–24
Figure 2. Rate of (a) death/myocardial infarction (MI), (b) death, and (c) MI at 48 h, 7 days, and 30 days, respectively, in relation to quartiles of C-reactive
protein (CRP). The number of patients with events is noted under the bars.
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separately. Furthermore, the independent associations to
outcome could also be demonstrated in multivariable analyses.
There was a very low 30-day mortality (1.1%) and MI
rate (2.5%) in patients without detectable TnT, in agree-
ment with previous studies (6,13). The mortality increased
with higher quartiles of TnT. In accordance with the
FRagmin during InStability in Coronary artery disease
(FRISC-II) study (14), any detectable TnT was associated
with a marked increased rate of MIs, probably reflecting a
thrombotic coronary lesion, with increased risk of subse-
quent occlusion and/or downstream embolization. How-
ever, patients in the highest compared with the two middle
quartiles had a trend toward a lower rate of MI, probably
due to a larger proportion of already completed MIs. Thus,
increasing TnT levels are associated with a continuous rise
in mortality, whereas any detectable TnT (i.e., 0.01 g/l)
is associated with a raised risk of MI without a significant
further risk at higher TnT levels. The frequent core labo-
ratory analyses of CK-MB and the rigorous MI definition
requiring a new episode of chest pain and new CK-MB
elevation make the possibility that an MI has resulted from
the same event as the initial TnT elevation unlikely.
In the present study, increased CRP levels during the
acute stage of unstable CAD were related to increased
mortality, in accordance with previous findings (5–8). In
this large patient cohort, this relation to increased mortality
was evident early and further accentuated throughout 30-
day follow-up. However, there was no association between
the CRP levels and the risk of MI, which has not been
shown previously. No previous study on inflammatory
markers in ACS has contained a sufficient number of
patients, enabling separation of the end points of death and
MI. However, for the placebo group (n  447) in the
Chimeric 7E3 AntiPlateleT in Unstable angina REfractory
to standard treatment (CAPTURE) trial, there was an
increased mortality in patients with CRP 10 mg/l, with-
out a corresponding rise in the occurrence of MI during the
initial six months (7). Also, the FRISC trial (n  965)
reported an increased mortality for patients with increasing
CRP levels, without any increase in the combined end point
of death/MI (5), indicating the absence of a relationship
between CRP levels and MI over a follow-up period of five
months.
The use of a positive troponin test as an inclusion
criterion might have influenced the associations between
troponin levels and outcome, but this seems unlikely given
that the relationship between TnT and CRP levels and
cardiac events was similar when the test was performed only
in the 5,756 patients included with the ST-segment depres-
sion criterion.
What might be the reason for the relationship between
CRP and subsequent mortality, but not MI, in the acute
phase of unstable CAD, despite the well-established rela-
tionship between CRP elevation and subsequent coronary
events in the chronic phase of atherosclerotic disease (2,15–
17)? In the acute phase of unstable CAD, the pronounced
elevation of CRP is transient and likely related to an
acute-phase reaction (18). Some patients with unstable
CAD might have a hyper-responsiveness of the inflamma-
tory system, which might exaggerate the acute-phase reac-
tion and increase the immune system reaction (19). Such a
mechanism is supported by the observations of co-
localization of CRP and activated complement in infarct-
related myocardium (20). C-reactive protein may contribute
to inflammation by activation of complement, which may,
in turn, mediate myocardial damage, induce arrhythmias,
and provoke contractile dysfunction (21). Such an interpre-
tation is in accordance with the relationships between the
CRP level and the occurrence of cardiac rupture, left
ventricular aneurysm formation, and mortality after acute
MI (22). The pronounced CRP elevation in unstable CAD
might also indicate a process different from the low-grade
CRP elevation in the chronic phase of atherosclerosis,
which is associated with subsequent coronary events among
healthy individuals (2,16,23) and after MI (17). In unstable
CAD and chronic atherosclerotic disease, there is a lasting
elevation of the fibrinogen level (18), which might indicate
an underlying chronic low-grade inflammatory condition
that is associated with a raised risk of later MI in both
conditions.
Despite the prognostic capacity of TnT regarding mor-
tality, adding CRP further improved the risk stratification.
On multivariable analysis, when correcting for a large
number of clinical risk factors, including TnT, increasing
CRP quartiles was an independent predictor of mortality.
With TnT and CRP as continuous variables, the ORs were
lower but still significant. Based on the present findings, the
combination of these two markers seems to identify three
Table 4. Mortality at 30 Days in Relation to Quartiles of Troponin T and C-Reactive Protein
Troponin T (g/l)
p Value*<0.01 0.01–0.12 0.12–0.47 >0.47
CRP (mg/l)
1.84 0.3 (2) 2.5 (12) 3.4 (13) 3.6 (9)  0.001
1.84–3.96 1.7 (9) 3.2 (14) 2.7 (12) 6.8 (24)  0.001
3.96–9.62 1.4 (6) 3.6 (14) 3.3 (16) 7.0 (33)  0.001
9.62 1.4 (5) 6.4 (20) 5.6 (24) 9.1 (62)  0.001
p value* 0.01 0.007 0.07 0.005
*Chi-squared test, linear-by-linear association. Data are presented as the percentage and number of patients in parentheses.
CRP  C-reactive protein.
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different risk groups (Tables 4 and 5) : one very low-risk
group without detectable TnT and CRP 1.84 mg/l; one
medium-risk group; and one high-risk group with TnT
0.47 g/l and CRP 9.62 mg/l, with corresponding
30-day mortality rates of 0.3%, 3% to 5%, and 9%,
respectively. These strata could prove useful in the selection
of more aggressive treatment for individual patients. Similar
relationships were found by Morrow et al. (8) in the
Thrombolysis In Myocardial Infarction (TIMI)-11A sub-
study (n 437), in which rapid TnT assays with a detection
limit of 0.2 g/l were used. However, in the current larger
study, the influence of CRP levels on mortality was evident
even in patients without any detectable TnT.
Study limitations. Our trial lacked information on left
ventricular function, cholesterol levels, and the type of
lipid-lowering treatment, all of which have importance for
subsequent mortality in the study population. Patients with
hypercholesterolemia at baseline had a statistically signifi-
cant (p  0.001) lower median level of CRP (3.7 vs. 4.1
mg/l), supporting the evidence that statin treatment reduces
CRP levels among survivors of MI (24). However, it is still
unknown whether this effect has any bearing on the im-
provement in outcome by statin treatment. In the present
study, the presence of hypercholesterolemia at baseline did
not influence the outcome. The causes of death were not
available, thus eliminating all opportunities for further
analysis of the mechanisms of mortality in the different
groups. GUSTO-IV included ACS patients with selected
risk criteria. The results are therefore primarily applicable to
a patient population with similar characteristics. However,
these characteristics are representative of a more general
ACS population (25). The event rate in GUSTO-IV was
also similar to previous trials on unstable CAD when
differences in definitions of MI are taken into consideration.
Clinical implications. In ACS, the levels of troponin and
CRP provide important, different, and complementary
prognostic information. With increasing levels of any of the
markers, there is a commensurate rise in mortality. At any
detectable troponin, there is also a raised risk of a later MI.
The combination of both markers allows the best prediction
of mortality. The use of the combination of these markers
will provide an important tool for the selection of patients
for clinical trials and also for identification of patients for
different treatment alternatives.
Reprint requests and correspondence: Dr. Stefan James, De-
partment of Cardiology, Thoraxcenter, Academic Hospital, 751 85
Uppsala, Sweden. E-mail: stefan.james@thorax.uas.lul.se.
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